The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Global’s (CGB) joint venture (JV) partner has been handed a key export permit, which will allow its cannabis hard pills to be shipped to Australia
  • Canntab Therapeutics has been given the green light by Health Canada, meaning Cann Global can begin importing the products
  • The patented pills from Canntab are unique as they allow for precise dosing
  • CGB plans to order six different products from the pill range
  • Among the pills Cann Global has ordered are two THC products, two CBD products and two THC/CBD blends
  • The products will begin arriving in Australia next month and will be available through the Special Access Scheme B and Authorised Prescriber schemes
  • Shares in Cann Global have opened Tuesday trading steady at 0.8 cents per share

Cann Global’s (CGB) joint venture (JV) partner has been handed a key export permit, which will allow its cannabis hard pills to be shipped to Australia.

Canntab Therapeutics has been given the green light by Health Canada, while Cann Global has already secured the necessary import permits for the pills.

Following the export permit being issued, Cann advises that its order of the hard pill products will begin arriving in Australia next month.

Canntab’s products are unique because of the patented hard pill form which they come in, which allows for more precise dosing.

CGB has ordered six different products from its JV partner, including two THC products, two CBD products and two THC/CBD blends.

The CBD and THC pills will be available in Australia through both the Special Access Scheme B and Authorised prescriber schemes.

Cann is also planning to make the pills available to the Cannabinoid Medicine Observational Study (CMOS) which is testing the efficacy of cannabis on neurological and mental health conditions.

Shares in Cann Global have opened Tuesday trading steady at 0.8 cents per share at 10:06 am AEDT.

CGB by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…